natgillin/translations-raw huggingface dataset:
In the event that the OL wishes to have the Disbursements made directly to the contractors/suppliers, such arrangement must be disclosed to, and be approved by, OpsCom and the Disbursement process must follow the procedures in the Bank's Disbursement Handbook. 
U slučaju da OL želi vršiti isplate izravno izvođačima/dobavljačima, o takvom je dogovoru potrebno obavijestiti te ga mora odobriti radni odbor, a postupak isplate sredstava mora slijediti procedure u Priručniku o načinima isplate Banke.
Please refer to the loan agreement dated [__________] (the "Loan Agreement") between [Name of Borrower] (the "Borrower") and European Bank for Reconstruction and Development (the "Bank"). 
Upućujemo Vas na ugovor o zajmu od dana [__________] ("Ugovor o zajmu") između [ime Zajmoprimca] ("Zajmoprimac") i Europske banke za obnovu i razvoj ("Banka").
[As soon as possible, on a date selected by the Bank in its discretion, but not later than] _________________________ 
[Što prije, na datum koji banka odabere prema vlastitom nahođenju, no najkasnije] _________________________
This date must not be earlier than 15 Business Days after the date the Disbursement application is delivered to the Bank. 
Taj datum mora biti najranije 15 radnih dana nakon datuma na koji je prijava za isplatu sredstava dostavljena banci.
Correspondent Bank name: 
Naziv korespondentne banke:
(a)all agreements, documents and instruments delivered to the Bank pursuant to Section 4.01 of the Loan Agreement are in full force and effect and unconditional (except for the Loan Agreement having become unconditional, if that is a condition of any such agreement); 
(a)su svi ugovori, dokumenti i instrumenti dostavljeni banci u skladu s odjeljkom 4.01. Ugovora o zajmu u potpunosti na snazi te bezuvjetni (osim Ugovora o zajmu koji je postao bezuvjetan ako je to uvjet nekog od tih ugovora);
(e)nothing has occurred which might have a material adverse effect on the Project, the Borrower's business, operations or financial condition or the ability of the Borrower to perform any of its obligations under any Financing Agreement or Project Agreement; 
(e)se nije dogodilo ništa što bi moglo imati negativan materijalni učinak na projekt, poslovanje, rad ili financijsko stanje Zajmoprimca ili mogućnost Zajmoprimca da ispuni bilo koju od svojih obveza prema Sporazumu o financiranju ili Sporazumu o projektu;
(g)the Borrower will retain all invoices from all contractors in respect of all payments to be made by it under this Disbursement and such invoices shall be made available to the Bank if the Bank so requests and the Borrower will provide access to the Bank staff for a review of such invoices: and 
(g)će Zajmoprimac zadržati sve račune svih izvođača, a koji se odnose na sva plaćanja koja mora izvršiti prema ovoj isplati sredstava, a ti računi moraju postati dostupni banci ako banka to zatraži, a Zajmoprimac će omogućiti osoblju banke pristup radi provjere tih računa: i
If any such representation or warranty is no longer true on or prior to or as of the date of such Disbursement, we shall immediately notify the Bank and shall, upon demand by the Bank, repay any amount which has been or is disbursed by the Bank in respect of such Disbursement. 
Ako takva izjava ili jamstvo nije više istinito na ili prije ili nakon datuma isplate sredstava, bez odgode ćemo o tome obavijestiti banku te ćemo, na zahtjev banke, vratiti sve iznose koje je banka isplatila ili isplaćuje, a koji se odnose na tu isplatu sredstava.
Currency of Contract 
Valuta ugovora
Amount of Contract: 
Iznos ugovora:
Date of Contract 
Datum ugovora
I hereby request <; [a further] pre-financing payment/payment of the balance>; under the Contract mentioned above. 
Ovim putem tražim <; [daljnju] isplatu predujma/isplatu razlike>; u skladu s navedenim Ugovorom.
Priority code and title: 
Kôd i naslov prioriteta:
GlobalP-Final 
Ukupni iznos - konačna isplata
To prepare the 'Request for Funds' 
Pripremiti "Zahtjev za sredstva"
PRE-FINANCING GUARANTEE (If the pre-financing payment requested exceeds 150.000 Euro) 
JAMSTVO ZA UPLAĆENI PREDUJAM (Ako traženi predujam prelazi 150.000,00 eura)
PRE-FINANCING GUARANTEE (amounts exceeding €150.000) 
JAMSTVO ZA UPLAĆENI PREDUJAM (iznosi iznad 150.000,00 €)
The total per budget line is not exceeded (check with previous payments and side letters / addenda 
Nije premašen ukupan iznos po proračunskoj liniji (provjeriti u prethodnim plaćanjima i popratnim pismima/prilozima
Financial guarantee is submitted (the pre-financing amount is more than the 80% of the contract amount and exceeds 60.000 EUR) 
Predano je financijsko jamstvo (iznos predujma viši je od 80% ugovornog iznosa i premašuje 60.000,00 eura)
Financial guarantee is submitted (the beneficiary is an NGO and the pre-financing amount is more than the 90% of the contract amount or more than 1.000.000 EUR) 
Predano je financijsko jamstvo (korisnik je nevladina organizacija, a iznos predujma viši je od 90% ugovornog iznosa ili premašuje 1.000.000,00 eura)
A report on the verification of the Action's expenditure is attached ( for any request for interim payments per financial year in case of grants of 750.000 EUR or more) 
Priloženo je izvješće o provjeri troškova Akcije (za svaki zahtjev za međuplaćanja po financijskoj godini u slučaju bespovratnih sredstava od 750.000,00 eura ili više)
A report on the verification of the Action's expenditure is attached (for any request for payment of the balance in the case of a grant of more than 100.000 EUR) 
Priloženo je izvješće o provjeri troškova Akcije (za svaki zahtjev za plaćanje razlike u slučaju bespovratnih sredstava iznad 100.000,00 eura)
A report on the verification of the Action's expenditure is attached( for any request for payment of over 100.000 EUR for the financial year, in the case of an operating grant) 
Priloženo je izvješće o provjeri troškova Akcije (za svaki zahtjev za plaćanje iznad 100.000,00 eura za financijsku godinu, u slučaju operativnih bespovratnih sredstava)
Initial Prefinancing the total amount of the grant is less than 100.000 EUR or less than 12 months implementation 
Početni predujam ukupan iznos bespovratnih sredstava niži je od 100.000,00 EUR ili je provedba kraća od 12 mjeseci
Initial Prefinancing the total amount of the grant is more than 100.000 EUR and above 12 months implementation 
Početni predujam ukupan iznos bespovratnih sredstava viši je od 100.000,00 EUR i provedba je dulja od 12 mjeseci
Further Prefinancing the total amount of the grant is more than 100.000 EUR and above 12 months implementation 
Daljnji predujmovi ukupni iznos bespovratnih sredstava viši je od 100.000,00 EUR i provedba je dulja od 12 mjeseci
Final Payment the total amount of the grant is less than 100.000 EUR or less than 12 months implementation 
Konačno plaćanje ukupni iznos bespovratnih sredstava niži je od 100.00,00 EUR ili je provedba kraća od 12 mjeseci
Final Payment the total amount of the grant is more than 100.000 EUR and above 12 months implementation 
Konačno plaćanje ukupni iznos bespovratnih sredstava viši je od 100.000,00 EUR i provedba je dulja od 12 mjeseci
day +1 from receipt of documents from the FM 
jedan dan od dana primitka dokumenata iz FM-a
If the termination letter deadline expires repossession immediately start, for which repossession agency can be involved. 
Ako istekne rok otkaznog pisma, oduzimanje odmah započinje, za što se može angažirati i agencija za oduzimanje.
Each single dose of Salmeterol/Fluticasone Pharos contains 
Svaka pojedina doza lijeka Salmeterol/Fluticasone Pharos sadržava
Salmeterol/Fluticasone Pharos contains two medicines packed in the two blisters of the single dose foil strips (double-blister strips), which are stored in the inhalation device Elpenhaler®. 
Salmeterol/Fluticasone Pharos sadržava dva lijeka pakirana u dva blistera u dvoslojnicama za jedinstvenu dozu koje se drže u uređaju za inhalaciju Elpenhaler®.
Each dose is pre-dispensed in one double-blister strip. 
Svaka je doza prethodno pripremljena u dvoslojnicu s dva blistera.
Each carton box contains one inhalation device Elpenhaler® with 30 double blister strips and one spare canister with 30 additional double blister strips. 
Svaka kartonska kutija sadržava jedan uređaj za inhalaciju Elpenhaler® s 30 dvoslojnica s dva blistera i jednim rezervnim spremnikom s 30 dodatnih dvoslojnica s dva blistera.
4.1 Therapeutic indications 
4.1 Terapijske indikacije
Salmeterol/Fluticasone Pharos is indicated in the regular treatment of asthma where use of a combination product (long-acting beta-2-agonist and inhaled corticosteroid) is appropriate: 
Salmeterol/Fluticasone Pharos indiciran je za redovito liječenje astme kad je prikladna uporaba kombinacije lijekova (dugodjelujući beta-2-agonist i inhalacijski kortikosteroid):
- Patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short acting beta-2-agonist 
- Bolesnici koji nemaju odgovarajuću kontrolu bolesti s inhalacijskim kortikosteridiima i, ,,po potrebi'', inhalacijskim kratkodjelujućim beta-2-agonistima
Salmeterol/Fluticasone Pharos is indicated for the symptomatic treatment of patients with COPD, with a FEV1 <;60% predicted normal (pre-bronchodilator) and a history of repeated exacerbations, who have significant symptoms despite regular bronchodilator therapy. 
Salmeterol/Fluticasone Pharos indiciran je u simptomatskom liječenju bolesnika s KOPB-om s FEV1 <; 60% od predviđenog normalnog (prije bronhodilatatora) i s ponovljenim egzacerbacijama u anamnezi koji imaju značajne simptome unatoč redovitoj terapiji bronhodilatatorom.
Salmeterol/Fluticasone Pharos is for inhalation use only. 
Salmeterol/Fluticasone Pharos isključivo se inhalira.
Patients should be made aware that Salmeterol/Fluticasone Pharos must be used daily for optimum benefit, even when asymptomatic. 
Bolesnicima se mora objasniti da za optimalni uspjeh liječenja Salmeterol/Fluticasone Pharos trebaju koristiti svakodnevno, čak i kad nemaju simptoma.
Patients should be regularly reassessed by a doctor, so that the strength of Salmeterol/Fluticasone Pharos they are receiving remains optimal and is only changed on medical advice. 
Liječnik mora redovito procjenjivati bolesnike kako bi snaga lijeka Salmeterol/Fluticasone Pharos koji primaju ostala optimalna, a doza se mijenja samo prema savjetu liječnika.
As an alternative, patients requiring a long acting beta-2-agonist could be titrated to Salmeterol/Fluticasone Pharos given once daily if, in the opinion of the prescriber, it would be adequate to maintain disease control. 
Kao alternativa, bolesnicima kojima je potreban dugodjelujući beta-2-agonist može se jednom dnevno titrirati Salmeterol/Fluticasone Pharos ako jeliječnika koji propisuje lijekove za održavanje kontrole bolesti smatra da je to prikladno.
In the event of once daily dosing when the patient has a history of nocturnal symptoms the dose should be given at night and when the patient has a history of mainly day-time symptoms the dose should be given in the morning. 
U slučaju doziranja jednom dnevno, u bolesnika s noćnim simptomima u anamnezi doza se mora davati noću, a u bolesnika u čijoj anamnezi prevladavaju dnevni simptomi doza se mora davati ujutro.
Patients should be given the strength of Salmeterol/Fluticasone Pharos containing the appropriate fluticasone propionate dosage for the severity of their disease. 
Bolesnicima se mora propisati jačina lijeka Salmeterol/Fluticasone Pharos koja sadržava dozu flutikazon propironata prikladnu za ozbiljnost njihove bolesti..
Prescribers should be aware that, in patients with asthma, fluticasone propionate is as effective as other inhaled steroids at approximately half the microgram daily dose. 
Liječnici koji propisuju lijekove moraju znati da je u bolesnika s astmom flutikazon propinonat jednako učinkovit kao i drugi udahnuti steroidi pri dnevnoj dozi od približno pola mikrograma.
One inhalation of 50 micrograms salmeterol and 250 micrograms fluticasone propionate twice daily 
Jedna inhalacija 50 mikrograma salmeterola i 250 mikrograma flutikazon propionata dva puta dnevno
One inhalation of 50 micrograms salmeterol and 500 micrograms fluticasone propionate twice daily. 
Jedna inhalacija 50 mikrograma salmeterola i 500 mikrograma flutikazon propionata dva puta dnevno.
A short term trial of Salmeterol/Fluticasone Pharos may be considered as initial maintenance therapy in adults with moderate persistent asthma (defined as patients with daily symptoms, daily rescue use and moderate to severe airflow limitation) for whom rapid control of asthma is essential. 
Kratkotrajno testiranje lijeka Salmeterol/Fluticasone Pharos može se smatrati početnom terapijom održavanja u odraslih s umjerenom trajnom astmom (definirani su kao bolesnici s dnevnim simptomima, dnevnom uporabom lijekova za olakšavanje simptoma i umjerenim do teškim ograničenjem protoka zraka) u kojih je osnovna brza kontrola astme.
In these cases, the recommended initial dose is one inhalation of 50 micrograms salmeterol and 100 micrograms fluticasone propionate twice daily. 
U takvim slučajevima preporučena je početna doza od jedne inhalacije 50 mikrograma salmeterola i 100 mikrograma flutikazon propionata dva puta dnevno.
Once control of asthma is attained treatment should be reviewed and consideration given as to whether patients should be stepped down to an inhaled corticosteroid alone. 
Kad se postigne kontrola astme, liječenje se mora provjeriti i mora se razmotriti može li se bolesnicima propisati samo inhalacijski kortikosteroid.
Regular review of patients as treatment is stepped down is important. 
Ako se terapija svede na jedan lijek, važno je redovito kontrolirati bolesnika.
Salmeterol/fluticasone propionate 50 microgram/100 micrograms strength is not appropriate in adults with severe asthma; it is recommended to establish the appropriate dosage of inhaled corticosteroid before any fixed combination can be used in patients with severe asthma. 
Salmeterol/Fluticasone Pharos u snazi od 50 mikrograma/100 mikrograma nije prikladan kod odraslih s teškom astmom; preporučuje se za uspostavljanje prikladnog doziranja inhaliranih kortikosteroida prije nego što se u bolesnika s teškom astmom upotrijebi trajna kombinacija.
There is no need to adjust the dose in elderly patients or in those with renal impairment. 
Nema potrebe za prilagođavanjem doze u starijih bolesnika ili u onih s oštećenjem bubrega.
There are no data available for use of salmeterol/fluticasone propionate in patients with hepatic impairment. 
Ne postoje podaci o uporabi salmeterol/flutikazon propionata u bolesnika s oštećenjem jetre.
Salmeterol/Fluticasone Pharos is contraindicated in patients with hypersensitivity (allergy) to any of the active substances or to the excipient (see section 6.1). 
Salmeterol/Fluticasone Pharos kontraindiciran je u bolesnika s preosjetljivošću (alergijom) na bilo koju od djelatnih ili pomoćnih tvari (vidi odlomak 6.1).
The management of asthma should normally follow a stepwise programme and patient response should be monitored clinically and by lung function tests. 
Liječenje astme treba normalno slijediti program korak po korak, a odgovor bolesnika mora se nadzirati klinički te uz pomoć testova plućne funkcije.
Patients should be advised to have their medicinal product to be used for relief in an acute asthma attack available at all times. 
Bolesnicima se mora savjetovati da uz sebe uvijek imaju lijek za olakšavanje simptoma u slučaju napada akutne astme.
Patients should not be initiated on Salmeterol/Fluticasone Pharos during an exacerbation, or if they have significantly worsening or acutely deteriorating asthma. 
Bolesnici ne smiju početi uzimati Salmeterol/Fluticasone Pharos tijekom egzacerbacije ili ako imaju znatno pogoršanje ili astmu koja se akutno pogoršava.
Serious asthma-related adverse events and exacerbations may occur during treatment with Salmeterol/Fluticasone Pharos. 
Tijekom liječenja sa Salmeterol/Fluticasone Pharosom mogu se javiti ozbiljni štetni događaji povezani s astmom i egzacerbacijom.
Patients should be asked to continue treatment but to seek medical advice if asthma symptoms remain uncontrolled or worsen after initiation on Salmeterol/Fluticasone Pharos. 
Bolesnicima se mora savjetovati da nastave liječenje, ali i da traže savjet liječnika ako simptomi astme nisu pod kontrolom ili ako se pogoršaju nakon početka uzimanja lijeka Salmeterol/Fluticasone Pharos.
Sudden and progressive deterioration in control of asthma is potentially life threatening and the patient should undergo urgent medical assessment. 
Iznenadno i progresivno pogoršanje u kontroli astme potencijalno je stanje opasno po život i bolesnik mora proći hitan liječnički pregled.
The patient should also be medically reviewed where the current dosage of Salmeterol/Fluticasone Pharos has failed to give adequate control of asthma. 
Bolesnik se također treba pregledati ako trenutačno doziranje lijeka Salmeterol/Fluticasone Pharos nije dovelo do odgovarajuće kontrole astme.
Once asthma symptoms are controlled, consideration may be given to gradually reducing the dose of Salmeterol/Fluticasone Pharos. 
Kad simptomi budu pod kontrolom, u obzir dolazi postupno smanjivanje doze lijeka Salmeterol/Fluticasone Pharos.
The lowest effective dose of Salmeterol/Fluticasone Pharos should be used (see section 4.2). 
U tu se svrhu koristi najniža učinkovita doza lijeka Salmeterol/Fluticasone Pharos (vidi odlomak 4.2.).
For patients with asthma or COPD, consideration should be given to additional corticosteroid therapies. 
Za bolesnike s astmom ili KOPB-om u obzir treba uzeti dodatno liječenje kortikosteroidima.
Treatment with Salmeterol/Fluticasone Pharos should not be stopped abruptly in patients with asthma due to risk of exacerbation. 
Liječenje s Salmeterol/Fluticasone Pharosom ne smije biti naglo prekinuto u bolesnika s astmom zbog rizika od egzacerbacije.
For patients with COPD cessation of therapy may also be associated with symptomatic decompensation and should be supervised by a physician. 
Za bolesnike s KOPB-om prekid liječenja može biti povezan s simptomatskom dekompenzacijom i liječnik ga mora nadzirati.
As with all inhaled medication containing corticosteroids, Salmeterol/Fluticasone Pharos should be administered with caution in patients with pulmonary tuberculosis. 
Kao i sa svim inhalacijskim lijekovima koji sadrže kortikosteroide, Salmeterol/Fluticasone Pharos se mora oprezno primjenjivati u bolesnika s tuberkulozom pluća.
Rarely, salmeterol and fluticasone propionate may cause cardiac arrhythmias e.g. supraventricular tachycardia, extrasystoles and atrial fibrillation, and a mild transient reduction in serum potassium at high therapeutic doses. 
Salmeterol i flutikazon priopionat rijetko mogu uzrokovati srčane aritmije, npr. supraventrikularnu tahikardiju, ekstrasistole i fibrilaciju atrija te umjereno prolazno smanjenje serumskog kalija pri visokim terapijskim dozama.
Therefore Salmeterol/Fluticasone Pharos should be used with caution in patients with severe cardiovascular disorders, heart rhythm abnormalities, diabetes mellitus, thyrotoxicosis, uncorrected hypokalaemia or patients predisposed to low levels of serum potassium. 
Stoga se lijek Salmeterol/Fluticasone Pharos mora oprezno upotrebljavati u bolesnika s teškim kardiovaskularnim poremećajima, poremećajima srčanog ritma, diabetesom mellitusom, tireotoksikozom, nekorigiranom hipokalemijom ili unbolesnika koji su skloni niskim razinama kalija u serumu.
There have been very rare reports of increases in blood glucose levels (see section 4.8) and this should be considered when prescribing to patients with a history of diabetes mellitus. 
Postoje rijetka izvješća o povećanim razinama glukoze u krvi (vidi odlomak 4.8.), što se mora uzeti u obzir prilikom propisivanja lijekova bolesnicima s diabetesom mellitusom u anamnezi.
As with other inhalation therapy paradoxical bronchospasm may occur with an immediate increase in wheezing after dosing. 
Kao i s drugom inhalacijskom terapijom, mogu se javiti paradoksalni bronhospazmi s iznenadnim pojačanjem sipnje nakon doziranja.
Salmeterol/Fluticasone Pharos should be discontinued immediately, the patient assessed and alternative therapy instituted if necessary. 
Odmah treba prestati uzimati lijek Salmeterol/Fluticasone Pharos, bolesnik se mora pregledati i, ako je to potrebno, treba uspostaviti alternativno liječenje.
Salmeterol/Fluticasone Pharos contains lactose. 
Salmeterol/Fluticasone Pharos sadržava laktozu.
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine. 
Bolesnici s rijetkim nasljednim bolestima, kao što su netolerancija galaktoze, Lappova deficijencija laktaze ili malapsorpcija glukoze-galaktoze, ne smiju uzimati ovaj lijek.
Care should be taken when transferring patients to Salmeterol/Fluticasone Pharos therapy, particularly if there is any reason to suppose that adrenal function is impaired from previous systemic steroid therapy. 
Treba biti oprezan prilikom promjene terapije bolesnicima na lijek Salmeterol/Fluticasone Pharos, osobito kad postoji sumnja na oštećenje funkcije nadbubrežne žlijezde uslijed prethodnog liječenja sustavnim steroidima.
Systemic effects may occur with any inhaled corticosteroid, particularly at high doses prescribed for long periods. 
Sustavni se učinci mogu javiti s bilo kojim inhalacijskim kortikosteroidima, osobito pri visokim dozama koje su propisane tijekom dužeg vremenskog razdoblja.
Possible systemic effects include Cushing's syndrome, Cushingoid features, adrenal suppression, growth retardation in children and adolescents, decrease in bone mineral density, cataract, glaucoma, and more rarely, a range of psychological or behavioural effects including psychomotor hyperactivity, sleep disorders, anxiety, depression or aggression (particularly in children). 
Mogući sustavni učinci uključuju Cushingov sindrom, Cushingoidne značajke, adrenalnu supresiju, usporavanje rasta u djece i adolescenata, smanjenje mineralne gustoće kostiju, katarakta, glaukom i, rjeđe, raspon psiholoških i bihevioralnih učinaka koji uključuju psihomotornu hiperaktivnost, poremećaje spavanja, anksioznost, depresiju ili agresiju (osobito u djece).
It is important, therefore, that the patient is reviewed regularly and the dose of inhaled corticosteroid is reduced to the lowest dose at which effective control of asthma is maintained. 
Stoga je važno da se bolesnici redovito pregledavaju i da doza inhaliranog kortikosteroida bude smanjena na najnižu dozu pri kojoj se održava učinkovita kontrola astme.
Presenting symptoms are typically vague and may include anorexia, abdominal pain, weight loss, tiredness, headache, nausea, vomiting, hypotension, decreased level of consciousness, hypoglycaemia, and seizures. 
Simptomi koji se javljaju tipično su nejasni i mogu uključivati anoreksiju, bol u želucu, gubitak težine, pospanost, glavobolju, mučninu, povraćanje, hipotenziju, suženu svijest, hipoglikemiju i napadaje.
Additional systemic corticosteroid cover should be considered during periods of stress or elective surgery. 
Tijekom stresnih razdoblja ili elektivnih zahvata može doći u obzir dodatno pokrivanje sustavnim kortikosteroidima.
The benefits of inhaled fluticasone propionate therapy should minimise the need for oral steroids, but patients transferring from oral steroids may remain at risk of impaired adrenal reserve for a considerable time. 
Prednosti liječenja inhalacijskim flutikazon propionatom trebaju smanjiti potrebu za oralnim steroidima, no bolesnici koji prelaze s oralnih steroida mogu i dalje imati rizik od oštećenja adrenalne rezerve tijekom dužeg vremenskog razdoblja.
Patients who have required high dose emergency corticosteroid therapy in the past may also be at risk. 
Bolesnici kojima je ranije bila potrebno liječenje visokim dozama kortikosteroida također su rizični.
This possibility of residual impairment should always be borne in mind in emergency and elective situations likely to produce stress, and appropriate corticosteroid treatment must be considered. 
Treba računati na mogućnost preostalih oštećenja u hitnim slučajevima i elektivnim situacijama koje vjerojatno uzrokuju stres te se mora uzeti u obzir prikladno liječenje kortikosteroidima.